What is the clinical impression for a 31‑year‑old male with chronic nausea since 2018, mild gastritis on gastroscopy, normal colonoscopy, current use of domperidone, ondansetron, and omeprazole, anxiety‑related anticipatory nausea, and mobility limitations?

Clinical Impression

This patient presents with chronic functional nausea and gastric dysmotility disorder, likely representing a disorder of gut-brain interaction (DGBI) with significant anxiety-mediated symptom amplification, showing encouraging clinical improvement with current multimodal therapy. 1

Primary Diagnosis

Chronic functional nausea with probable gastric motor dysfunction, classified as a disorder of gut-brain interaction per Rome IV criteria. 1 The clinical presentation—chronic nausea since 2018 triggered by movement, meals, and positional changes, with mild gastritis on endoscopy but otherwise unremarkable structural investigations—strongly suggests a functional gastric disorder rather than structural pathology. 1

Key Diagnostic Features Supporting This Impression:

• Motion-triggered and positional nausea (worsened by stairs, long drives, lying on side) suggests vestibular-gastric axis dysfunction or autonomic dysregulation. 1
• Postprandial symptom exacerbation with larger/richer meals indicates impaired gastric accommodation or delayed gastric emptying. 1, 2
• Morning nausea improving with upright position may reflect nocturnal gastric stasis or esophageal reflux component. 2
• Mild gastritis on gastroscopy is insufficient to explain the severity and chronicity of symptoms, pointing toward functional rather than inflammatory etiology. 2

Secondary Diagnosis

Anxiety disorder with anticipatory nausea and health-related anxiety, contributing significantly to symptom perpetuation and disability. 1 The patient exhibits:

• Anxiety specifically related to medical visits and past severe nausea episodes. 1
• Anticipatory nausea linked to previous traumatic symptom experiences. 1
• Mobility limitations requiring walking stick outdoors, suggesting functional impairment beyond what mild gastritis would typically cause. 1

The bidirectional relationship between anxiety and gastrointestinal symptoms is well-established in DGBIs, where psychological distress amplifies visceral hypersensitivity and autonomic dysfunction. 1

Differential Considerations to Exclude

Gastroparesis

• Formal gastric emptying study (4-hour scintigraphy) is indicated to definitively rule out or confirm delayed gastric emptying, as this would significantly alter management. 1, 2, 3
• The symptom profile (postprandial fullness, nausea, early satiety) overlaps substantially with gastroparesis. 2, 4
• Awaiting CT results is appropriate, but gastric emptying scintigraphy remains the gold standard diagnostic test. 2, 3

Cannabinoid Hyperemesis Syndrome (CHS)

• Must be explicitly excluded through detailed substance use history, as the patient denies drug use but CHS can present with chronic cyclical nausea and compulsive bathing behavior. 1
• CHS requires cannabis use >1 year with frequency >4 times weekly, and symptoms resolve with 6-month abstinence. 1

Hypermobile Ehlers-Danlos Syndrome (hEDS) or Hypermobility Spectrum Disorder (HSD) with POTS

• Consider screening for joint hypermobility and orthostatic intolerance, given the mobility limitations, motion-triggered symptoms, and chronic GI complaints. 1
• Patients with hEDS/HSD have high prevalence of gastric motor dysfunction and autonomic dysregulation (POTS), which could explain both GI and mobility symptoms. 1
• If clinical suspicion exists, formal gastric emptying testing and autonomic function testing (tilt-table) should be pursued. 1

Current Medication Regimen Assessment

Appropriate Components:

• Domperidone 10 mg TID is correctly dosed as a third-line prokinetic for functional nausea and potential gastric dysmotility. 5, 6, 4
• Ondansetron 8 mg PRN up to TID is appropriate as a second-line 5-HT3 antagonist for breakthrough nausea. 1, 6
• Omeprazole 40 mg BID is reasonable given documented mild gastritis, though the dose is higher than typically needed for non-erosive gastritis. 1

Critical Safety Monitoring Required:

• Baseline and periodic EKG monitoring is mandatory due to QT-prolonging effects of both domperidone and ondansetron when used concurrently. 5, 6
• Electrolyte monitoring (potassium, magnesium) should be performed regularly, as hypokalemia/hypomagnesemia potentiate QT prolongation risk. 5
• Drug interaction assessment: Domperidone and ondansetron share CYP3A4 metabolism, though ondansetron does not significantly inhibit domperidone hydroxylation in vitro. 7

Medication Optimization Considerations:

• Cyclizine discontinuation was appropriate due to documented interaction with domperidone. 5
• Consider adding a neuromodulator (tricyclic antidepressant or SSRI) to address both visceral hypersensitivity and anxiety, which may reduce overall symptom burden more effectively than antiemetics alone. 1, 8

Prognostic Indicators

Favorable Signs:

• Noticeable mobility improvement over past 2 weeks suggests either natural symptom fluctuation or treatment response. 1
• Less severe recent episodes without wheelchair requirement indicates positive trajectory. 1
• Improved handling of medical appointments suggests developing coping mechanisms for anticipatory anxiety. 1

Concerning Features:

• Seven-year symptom duration (since 2018) indicates chronicity that may require long-term multimodal management. 1
• Mobility limitations requiring walking stick in a 31-year-old suggests significant functional impairment beyond typical DGBI presentation. 1
• Temporal association with oxybutynin use in 2017 raises question of medication-induced autonomic dysfunction that may have persisted. 1

Recommended Diagnostic Workup

Essential Next Steps:

1. 4-hour gastric emptying scintigraphy to definitively assess for gastroparesis, as this will determine whether prokinetic therapy is mechanistically appropriate. 1, 2, 3
2. Review pending CT scan results to exclude structural pathology (mass, obstruction, vascular compression). 1
3. Formal autonomic testing (tilt-table, heart rate variability) if clinical features suggest POTS (orthostatic symptoms, motion intolerance, mobility limitations). 1

Adjunctive Investigations to Consider:

• Celiac serology (tissue transglutaminase IgA with total IgA), as celiac disease can present with chronic nausea and is more prevalent in patients with hypermobility disorders. 1
• Body surface gastric mapping (BSGM) if available, as recent evidence shows this noninvasive technology can distinguish gastric neuromuscular dysfunction from brain-gut dysregulation in chronic nausea syndromes. 3
• Psychological assessment with validated instruments (GAD-7, PHQ-9) to quantify anxiety and depression severity for treatment planning. 1

Management Recommendations

Pharmacological Optimization:

Add a neuromodulator to address both visceral pain/nausea and anxiety, as current regimen focuses solely on antiemetic/prokinetic mechanisms without addressing central sensitization or psychological comorbidity. 1, 8

• First-line option: Amitriptyline 25 mg at bedtime, titrated by 25 mg weekly to 75-100 mg as tolerated, which addresses visceral hypersensitivity, anxiety, and may improve sleep. 6, 8
• Alternative if anticholinergic side effects are problematic: Duloxetine 30 mg daily, titrated to 60 mg, which addresses both anxiety and visceral pain through SNRI mechanism. 8
• If nausea is refractory: Mirtazapine 7.5-15 mg at bedtime, which has demonstrated efficacy specifically for refractory nausea in gastroparesis and has anxiolytic properties. 8

Non-Pharmacological Interventions:

• Cognitive behavioral therapy (CBT) for health anxiety and anticipatory nausea should be initiated promptly, as brain-gut behavioral therapies have demonstrated efficacy in DGBIs with psychological comorbidity. 1
• Dietary modifications: Continue small, frequent meals with low-fat, low-fiber content; consider liquid calorie supplementation if solid food tolerance remains poor. 6, 2
• Gradual exercise reconditioning program to address deconditioning and autonomic dysfunction, starting with short walks and progressive resistance training. 1

Follow-Up Plan:

• Gastroenterology follow-up in 4-6 weeks after gastric emptying study results to reassess medication regimen based on objective findings. 1, 6
• Psychology/psychiatry referral for formal CBT and anxiety management, with consideration for integrated multidisciplinary care model. 1
• EKG and electrolyte monitoring every 3 months while on concurrent domperidone and ondansetron. 5

Critical Clinical Pitfalls to Avoid

• Do not escalate domperidone beyond 10 mg TID (30 mg/day total) due to cardiovascular safety concerns, particularly QT prolongation and ventricular arrhythmia risk. 5, 6, 4
• Avoid opioid analgesics, as they worsen gastric emptying and nausea while carrying high addiction risk in chronic conditions. 1
• Do not dismiss mobility limitations as purely psychological—they may indicate underlying autonomic dysfunction (POTS) or connective tissue disorder (hEDS/HSD) requiring specific evaluation and treatment. 1
• Recognize that normal endoscopy and colonoscopy do not exclude significant gastric motor dysfunction—functional testing is required for definitive diagnosis. 2, 3